How to Live to 200 Podcast

Martin Tobias is the CEO of Bulletproof Labs, the CEO of Upgrade Labs and the co-founder of People For Cause, Element 8 Angels, and MGT Investments. He’s served on the board of directors for Cloudmark and Tippr, and co-founded numerous startups, including Kashless, Imperium Renewables, and Loudeye Technologies. He was a partner at Ignition Partners, a venture capital firm in Seattle, and previously served as an executive at Microsoft.

In addition to being an experienced technology executive, Martin is a health enthusiast and an advocate for people taking control of their own biology. Bulletproof Labs is a high-end health center with an emphasis on biohacking. Bulletproof Labs features the latest, cutting-edge workout equipment and experimental and emerging therapies, including cryotherapy, float tanks, and high-intensity interval training.

In this episode, we answer questions on biohacking and discuss the latest trends in life extension. What are telomeres? Can you regrow your telomeres? What are NAD supplements? Could nicotine be part of a healthy diet? What is a vampire facial?

• bulletprooflabs.com
• Martin Tobias Twitter
• Martin's Personal Blog

• Palo Alto Longevity Prize
• 40 years of Zen
• Telomere extension turns back aging clock in cultured human cells, study finds
• Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells
• Nicotinamide adenine dinucleotide (NAD)
• NAD+ and sirtuins in aging and disease, Shin-ichiro Imai, Leonard P. Guarente
• BrainCheck
• Martin’s blog on NAD supplementation: DO THIS: Increase your NAD levels
• TRU NIAGEN
• Elysium Basis
• Bulletproof Labs' Body Hacks
• Bulletproof products
• Will a Nicotine Patch Make You Smarter? [Excerpt]
• Platelet-rich Plasma (PRP)
• Oura
• DO THIS: Morning Pages Hacks
• DAVID Delight Pro
• Muse

Our guest today needs no introduction. It is the one and only Aubrey de Grey, a leading biomedical gerontologist, computer scientist, author, and entrepreneur whose work in longevity research is widely known and regularly referenced by many in the industry. He is the Chief Science Officer of the SENS Research Foundation and VP of New Technology Discovery at AgeX Therapeutics, Inc. In many respects, Aubrey is one of the most prominent, if not provocative figures in longevity science.

What makes Aubrey so provocative? Well, aside from his exceptionally long beard, he is the leading advocate of the controversial view that technology may one day enable humans to control the aging process and live well into our hundreds, or even thousands. As much as he believes this, he also knows that there are two main obstacles to achieving this utopia: money and time. While Aubrey’s research is funded by some of the biggest investors, he notes that the “pro-aging trance” has historically held them back. This conversation with Aubrey uncovers the theory of his pro-aging trance phenomena and many incredibly insightful details, including:

• How to remove senescent cells from our body
• What investments are at the top of his list
• Why investor Peter Thiel gave him $6M in funding
• What locations are hot spots for longevity research and innovation
• Where he’s seen the biggest breakthroughs
• When we can expect to benefit from his research
• What is the “pro-aging trance” and why it’s holding us back

This was a really exciting episode that gave the team a chance to hear a unique perspective. We hope you enjoy the episode and share it with your friends, family, and colleagues.

• Aubrey de Grey
• Aubrey de Grey on Twitter

• Sens.org
• Senolytics
• Unity Biotechnology
• Peter Thiel
• Insilico medicine
• Aubrey de Grey – Living to 1000 Years Old
• Ending Aging by Aubrey de Grey

Our guest today is Matt Kaeberlein, Ph.D., a globally recognized researcher and expert in the biology of aging. Dr. Kaeberlein’s research is based around the premise that understanding the molecular mechanisms of aging will lead to interventions that slow the onset and progression of age-related chronic conditions, such as cancer, diabetes, kidney disease, heart disease, Alzheimer’s and others. Dr. Kaeberlein received his Ph.D. from the Massachusetts Institute of Technology in 2002 advised by Leonard Guarente, and did his post-doctoral work with Stanley Fields in the Department of Genome Sciences at the University of Washington.

Dr. Kaeberlein’s expertise in dietary restriction, longevity genes for therapeutics, aging in dogs, and Rapamycin really shines in this conversation. We were lucky enough to really explore his background while sharing our collective love of dogs. The conversation explores many areas, including:

• What is the difference between calories restriction and dietary restriction
• What are the biggest challenges with the science
• How Matt thinks about tailored dietary advice
• Why Matt launched the Dog Aging Project
• What we can learn from his research with dogs
• What is Rapamycin and why he’s so interested in its effects

This conversation was incredibly illuminating and really fun. We hope you enjoy the episode and share it with your friends, family, and colleagues.

• Matt Kaeberlein
• Matt Kaeberlein Twitter

• Next Generation sequences
• Metabolomics
• Epigenetic clocks
• Calorie Restriction Society
• TAME Trial
• Rapamycin
• Daniel Promislow
• Dog Aging Project
• Acarbose
• NIA Interventions Testing Program
• Shock center of excellence
• George M. Martin
• Rapalog Everolimus

Most of us watch reality TV shows to escape our responsibilities and indulge in something less than wholesome. Today's guest found something interesting nestled in her indulgence. While watching the Fox reality TV show The Swan, famed author and investor Sonia Arrison detected the pending human longevity revolution that was just around the corner. She began investigating the effects that increased human longevity would have on society, culminating in her book 100 Plus: How the Coming Age of Longevity Will Change Everything, From Careers and Relationships to Family and Faith.

While we at L200 are still wondering what it looks like to live to 200, Sonia literally wrote the book on what it means to live past 100. Sonia's interest in human longevity started long before her encounter with The Swan. As a young girl, she noticed that while her grandparents were aging quite well, others did not fare so well. This sparked her curiosity and set her on a lifelong journey in longevity science.

Today, Sonia and her team at 100 Plus Capital invest in some of the most innovative companies positively impacting human longevity. As an active investor, Board Member at the Thiel Foundation, and a Senior Fellow at the Fraser Institute, Sonia’s research and intuition delivers a unique perspective that proved highly-engaging in our conversation. During this podcast, we explore Sonia's investment focus, her diverse background, and her view on a number of interesting topics, including:

• What has changed since Sonia wrote her book
• Why longevity is good for economic growth
• What are the hot longevity topics at Silicon Valley cocktail parties
• What investment categories are interesting for Sonia
• Where she sees the most innovation
• How 911 changed her perspective on human health
• What Sonia thinks of the latest trends/fads (e.g. Keto, fasting)

This was an incredible episode that left our team feeling optimistic and energized. Be sure to catch the (new) lightning round at the end of the episode for Sonia’s take on the latest and greatest trends in healthy living!

• Sonia’s Website
• Sonia Arrison’s Twitter

• Senolytics
• Daniel Kraft, MD
• Gerry Becker, The Economic Way of Looking at Life
• Implications of Population Aging for Economic Growth - David canning and David Bloom
• CIA longevity factbook
• The Ocean Cleanup
• L- nutra, ProLon
• Blumio
• 5-2 diet
• Parabiosis
• Aubrey de Grey
• UCSF Memory and Aging Center
• Johnson & Johnson Anti-Aging
• Calico
• Unity Biotechnology

On this week’s episode of the How to Live to 200 podcast, we speak with Liz Parrish, CEO of BioViva. Join us as we go on a journey as we learn about Liz’s highly controversial medical tourism trip and the experimental gene therapies she’s using to cure aging. While many of our guests explore the boundaries of accepted treatments and standards, Liz’s experimentation takes things to a new level.

As CEO of BioViva, Liz works diligently to push accelerate innovation in gene therapy while democratizing critical information about the benefits of these new, bleeding-edge therapies. During this eye-opening conversation, we learn about the diagnoses that kickstarted her entrepreneurial journey to find a cure for kids. Along the way, we get a glimpse into the experimental world of gene therapies and the exciting new trends that Liz expects to see in the next wave of medicine. In this episode, we find out:

• Why is Medical tourism big in Columbia?
• What is the process of taking experimental gene therapies?
• What results did Liz have after her gene therapies?
• What is the delivery mechanism for gene therapies?
• What is the future of telomerase injection?

If you’ve ever considered medical tourism, this episode is for you. We really enjoyed getting an in-depth look at the little-known world of medical tourism and the role it plays in pushing new treatments. Sit back, relax, and join us as we venture into the unknown.

• BioViva
• Liz Parrish on Twitter

• Progeria
• SENS Research Foundation
• George Church
• Sierra Sciences
• Telomerase
• SpectraCell telomere testings
• Myostatin
• Viral vector
• Integrated Health Systems
• Klotho
• PGC-1alpha
• hTERT
• Follistatin
• How to Read a Paper, Trisha Greenhalgh
• Buck Institute
• Right-to-try law
• Cochrane
• CAR T Cell Therapy
• GDF11 peptides